You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
雅各臣科研製藥(02633.HK)擬增持品牌中藥業務並子公司引入戰投
格隆匯 07-27 21:02

格隆匯7月27日丨雅各臣科研製藥(02633.HK)宣佈,於2020年7月27日,公司間接全資附屬公司Sampan Development Limited擬向楊樺收購目標公司Orizen Capital Limited10%股份,代價為3000萬港元,將透過由健倍苗苗(為公司間接全資附屬公司)向楊樺發行3000萬股健倍苗苗股份的方式償付,構成公司視作出售一家附屬公司的股權。

據悉,目標公司為於英屬處女羣島註冊成立的投資控股公司。於公告日期,目標公司為公司間接非全資附屬公司,而目標集團主要從事品牌中藥業務,其以不同品牌名稱(包括目標集團擁有的品牌名稱)銷售和分銷濃縮中藥顆粒產品。

透過先前進行的收購事項,公司自2019年8月起已透過買方間接收購目標公司合共88%的權益。香港附屬公司於截至2020年3月31日止年度的除税前純利錄得5.4%的穩健增長。透過增加目標公司股權及公司重組,我們得以進一步鞏固我們對目標集團品牌中藥業務的控制權。此舉亦強化集團追求的收購方針,以切合業務組合的策略所需,併為股東創造長期價值。

此外,於公告日期的同日,健倍苗苗及JBM Group (BVI) Limited(公司直接全資附屬公司及健倍苗苗直接控股公司)分別與若干戰略投資者訂立戰略投資協議,預期將於完成落實當日完成。根據戰略投資協議,戰略投資者同意認購且健倍苗苗同意配發及發行合共9700萬股新股份,每股認購價1港元與代價股份的每股發行價格相同。

於完成及戰略投資協議完成後,楊樺及戰略投資者分別持有健倍苗苗經擴大股本約3.53%及11.43%。公司將間接持有健倍苗苗經擴大股本約85.04%。l

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account